Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate CancerPhilip W. Kantoff, Wayne R. Godfrey, James L. Gulley et al.|Journal of Clinical Oncology|2010Cited by 973
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate CancerJames L. Gulley, William L. Dahut, Philip M. Arlen et al.|Clinical Cancer Research|2005Cited by 371
Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune ResponsesJohn L. Marshall, Jeffrey Schlom, Robert J. Hoyer et al.|Journal of Clinical Oncology|2000Cited by 357
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialRavi A. Madan, James L. Gulley, Mahsa Mohebtash et al.|The Lancet Oncology|2012Cited by 327
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerJames L. Gulley, Jeffrey Schlom, Philip M. Arlen et al.|Cancer Immunology Immunotherapy|2009Cited by 298